Efficacy of SGLT2 inhibitors for the reduction of cardiovascular death and heart failure hospitalization among non-diabetic heart failure patients: a meta-analysis
Efficacy and safety of the dual SGLT1 and 2 inhibitor sotagliflozin in combination with a mineralocorticoid receptor antagonist in patients hospitalized for worsening heart failure